ADiTx Therapeutics Inc. (ADTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADTX Stock Price Chart Interactive Chart >
ADTX Price/Volume Stats
|Current price||$0.29||52-week high||$3.95|
|Prev. close||$0.27||52-week low||$0.24|
|Day high||$0.30||Avg. volume||623,387|
|50-day MA||$0.36||Dividend yield||N/A|
|200-day MA||$0.92||Market Cap||12.97M|
ADiTx Therapeutics Inc. (ADTX) Company Bio
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.
Most Popular Stories View All
ADTX Latest News Stream
|Loading, please wait...|
ADTX Latest Social Stream
View Full ADTX Social Stream
Latest ADTX News From Around the Web
Below are the latest news stories about Aditxt Inc that investors may wish to consider to help them evaluate ADTX as an investment opportunity.
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
RICHMOND, Va., January 18, 2022--Aditxt, Inc. ("Aditxt," or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity’s transition to the "Age of Immunity," has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body’s immune response to COVID-19.
Aditxt, Inc. to Participate in Edison Group’s Global Healthcare "Open House" Virtual Conference From January 25th-27th, 2022
RICHMOND, Va., January 14, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
RICHMOND, Va., January 12, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.
NEW YORK, NY / ACCESSWIRE / December 31, 2021 / Lifshitz Law Firm, P. is investigating possible breaches of fiduciary duty by the board of directors of Aditxt, Inc.
Halper Sadeh LLP Investigates LAWS, ADTX, EPAY, SKIL, HXOH; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
ADTX Price Returns